Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting.
SNDS
immunotherapy
interstitial lung disease
nivolumab
non-small cell lung cancer
survival
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2023
2023
Historique:
received:
27
09
2022
accepted:
05
01
2023
entrez:
6
2
2023
pubmed:
7
2
2023
medline:
7
2
2023
Statut:
epublish
Résumé
Up to 10% of patients with advanced non-small cell lung cancer (aNSCLC) have pre-existing interstitial lung disease (ILD). These patients are usually excluded from immunotherapy clinical trials. Consequently, knowledge on outcomes following nivolumab treatment in these patients remains limited. The primary objective of this study was to evaluate survival outcome following nivolumab treatment in ILD patients with pre-treated aNSCLC in the real-world setting. The study included all patients with aNSCLC recorded in the French hospital database, starting nivolumab in 2015-2016. Patients were stratified by pre-existing ILD and three subgroups were studied [auto-immune or granulomatous (AI/G) ILD, other known causes ILD and idiopathic ILD]. Time to discontinuation of nivolumab treatment [time to treatment duration (TTD)] and overall survival (OS) were estimated using Kaplan-Meier survival analysis. Of 10,452 aNSCLC patients initiating nivolumab, 148 (1.4%) had pre-existing ILD. Mean age at nivolumab initiation was 64.6 ± 9.4 years in ILD and 63.8 ± 9.6 years in non-ILD. Compared to non-ILD, patients in the ILD group were more frequently men ( In this large cohort of aNSCLC patients with ILD, outcomes are similar to those obtained in the non-ILD population. Immunotherapy could be beneficial for these patients.
Sections du résumé
Background
UNASSIGNED
Up to 10% of patients with advanced non-small cell lung cancer (aNSCLC) have pre-existing interstitial lung disease (ILD). These patients are usually excluded from immunotherapy clinical trials. Consequently, knowledge on outcomes following nivolumab treatment in these patients remains limited. The primary objective of this study was to evaluate survival outcome following nivolumab treatment in ILD patients with pre-treated aNSCLC in the real-world setting.
Patients and methods
UNASSIGNED
The study included all patients with aNSCLC recorded in the French hospital database, starting nivolumab in 2015-2016. Patients were stratified by pre-existing ILD and three subgroups were studied [auto-immune or granulomatous (AI/G) ILD, other known causes ILD and idiopathic ILD]. Time to discontinuation of nivolumab treatment [time to treatment duration (TTD)] and overall survival (OS) were estimated using Kaplan-Meier survival analysis.
Results
UNASSIGNED
Of 10,452 aNSCLC patients initiating nivolumab, 148 (1.4%) had pre-existing ILD. Mean age at nivolumab initiation was 64.6 ± 9.4 years in ILD and 63.8 ± 9.6 years in non-ILD. Compared to non-ILD, patients in the ILD group were more frequently men (
Conclusion
UNASSIGNED
In this large cohort of aNSCLC patients with ILD, outcomes are similar to those obtained in the non-ILD population. Immunotherapy could be beneficial for these patients.
Identifiants
pubmed: 36743523
doi: 10.1177/17588359231152847
pii: 10.1177_17588359231152847
pmc: PMC9893351
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17588359231152847Informations de copyright
© The Author(s), 2023.
Déclaration de conflit d'intérêts
VG, CC, FEC, AFG, and DR are employees of BMS. BJ and RJ are employees of HEVA. JBA, HN, and CC report no conflict of interest. BD reports personal fees for medical training for BMS, Roche, Pfizer, Astra Zeneca, Chiesi, Amgen, Lilly and congress fees from Astra Zeneca, Pfizer and Oxyvie.
Références
Oncologist. 2019 Aug;24(8):1013-1021
pubmed: 31088979
JAMA Oncol. 2018 Mar 01;4(3):374-378
pubmed: 28975219
BMC Pulm Med. 2019 Aug 22;19(1):156
pubmed: 31438923
Am J Respir Cell Mol Biol. 2018 Jun;58(6):684-695
pubmed: 29220578
BMC Cancer. 2021 Jun 24;21(1):726
pubmed: 34167516
Lung Cancer. 2020 Feb;140:99-106
pubmed: 31911324
Lung Cancer. 2018 Nov;125:212-217
pubmed: 30429022
Transl Lung Cancer Res. 2021 Jun;10(6):2937-2954
pubmed: 34295689
Lung Cancer. 2021 May;155:120-126
pubmed: 33798901
J Clin Oncol. 2018 Jul 1;36(19):1905-1912
pubmed: 29746230
Chest. 2019 Apr;155(4):e79-e82
pubmed: 30955583
Clin Lung Cancer. 2018 Sep;19(5):e667-e673
pubmed: 29844002
Med Oncol. 2019 Apr 27;36(6):49
pubmed: 31030326
Chest. 2019 Dec;156(6):1195-1203
pubmed: 31404527
J Thorac Oncol. 2011 Jul;6(7):1242-6
pubmed: 21623239
J Clin Oncol. 2021 Mar 1;39(7):723-733
pubmed: 33449799
Lung Cancer. 2021 Jul;157:40-47
pubmed: 33980420
Front Oncol. 2019 Jun 06;9:478
pubmed: 31245290
J Thorac Dis. 2018 Jun;10(6):3829-3844
pubmed: 30069384
Oncoimmunology. 2020 Apr 12;9(1):1744898
pubmed: 33457089
Lung Cancer. 2016 Jun;96:63-7
pubmed: 27133752
Eur J Cancer. 2021 Mar;145:179-182
pubmed: 33486441
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
JCO Precis Oncol. 2018 Nov;2:1-24
pubmed: 35135139
Am J Respir Crit Care Med. 2008 Jun 15;177(12):1348-57
pubmed: 18337594
Thorac Cancer. 2020 Nov;11(11):3317-3325
pubmed: 32986306
Ther Adv Med Oncol. 2020 Oct 26;12:1758835920967237
pubmed: 33403011
J Thorac Oncol. 2020 Dec;15(12):1935-1942
pubmed: 32858235
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753
ERJ Open Res. 2021 Jan 25;7(1):
pubmed: 33532484
Am J Respir Crit Care Med. 2015 Jul 15;192(2):e3-19
pubmed: 26177183
Lung Cancer. 2019 Aug;134:274-278
pubmed: 31182249
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Eur Respir J. 2017 Aug 3;50(2):
pubmed: 28775045
Respir Investig. 2018 Sep;56(5):375-383
pubmed: 30061050
Lung Cancer. 2017 Sep;111:1-5
pubmed: 28838377